thought call
thought lilli perform solid revenu non-gaap
ep higher sg overshadow lower outlook reflect
known impact recent loxo acquisit lartruvo failur view
weak today overdon given revis line expect
dont chang stori differenti growth biopharma inde repres
slower year top line growth midpoint non-gaap ep
updat outlook look beatabl forecast respect
lilli growth profil remain unchang compound-annual-growth-rate still intact
suspect new product cycl metabol immunolog
oncolog franchis trulicity/jardi taltz verzenio could continu surpris
upsid outweigh loe lartruvo headwind beyond franchis lilli
updat time full elanco separ could near term faster
versu prior commentari could minim disrupt ep risk
estim rang depend off-set share repo
overal lilli remain favor name us pharma space given differenti
long-term growth profil later stage pipelin high impact later-stag
asset low expect includ tanezumab pain baricitinib olumi ad
lasmiditan migrain ramucirumab nsclc maintain ow rate pt
near-term catalyst drive momentum recogn
strong run point sever event could drive upsid current level
rewind june follow increas class expans long-term
safeti tanezumab file minim expect pain
upsid elanco spin data libretto
model chang given perform updat guidanc expect
revenu non-gaap ep estim move
figur page detail
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight exit yz period
new commerci stage portfolio attract diabet
oncolog immunolog asset model
forecast mid single-digit sale low double-digit
ep growth major
pharma averag execut product
cadenc think current multipl
faster expect commerci launch
expect jardianc trulic taltz
baricitinib could drive upsid potenti
multipl expans
slow uptak new diabet immunolog
margin pressur early/intermedi pipelin
failur could caus concern long term
million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell million except per share itemspriorcurr chg sell incom expens net ep outstand analysispriorcurr chg chg bp gross sell changepriorcurr chg chg sell barclay eli lilli co
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
